<DOC>
	<DOCNO>NCT02652793</DOCNO>
	<brief_summary>A 48-week , open label , non comparative prospective trial stable chronic human immunodeficiency virus-infected patient achieve complete virological suppression 24 week ( human immunodeficiency virus-1 RNA &lt; 50 c/ml ) switch antiretroviral regimen contain tenofovir lamivudine emtricitabine boost protease inhibitor boost atazanavir lamivudine Study visit take place screening , baseline , week 4 , 12 , 24 , 48 .</brief_summary>
	<brief_title>Simplification From Tenofovir Plus Lamivudine Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor Ritonavir-Boosted-Atazanavir Plus Lamivudine Virologically-Suppressed-HIVInfected Adults With Osteopenia</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Human immunodeficiency virus1infected subject age â‰¥18 year old Hip spine Tscores &lt; 1.0 &gt; 2.5 dualenergy Xray absorptiometry ( previous 24 week ) Stable antiretroviral treatment base tenofovir lamivudine emtricitabine boost protease inhibitor least 24 week . Having plasma human immunodeficiency virus1 RNA &lt; 50 copies/mL least previous 24 week , include least two sample . Pregnancy , breastfeed status plan pregnancy short term Primary genotypic resistance mutation and/or previous virological failure atazanavir lamivudine/emtricitabine Chronic hepatitis B infection Patients indication therapy prevention bone fracture 25OH vitamin D deficiency ( &lt; 10ng/mL ) Hypogonadism ( low total testosterone accord local reference range ) Hypothyroidism ( low T4 increase thyroid stimulate hormone level accord local reference range ) Hyperparathyroidism ( increase parathyroid hormone level hypercalcaemia accord local reference range ) Having receive oral corticosteroid inhale fluticasone ( daily dose high 5 mg/d prednisone equivalent 3 month ) Using antiresorptive therapy ( Calcium vitamin D supplement encourage mandate ) Body mass index lower 19</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>